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Accepted 9 January 2013AbstractObjective: As psychopathology and social functioning can worsen with repeated psychotic episodes in schizophrenia, relapse preven-
tion is critical. Because high nonadherence rates limit the efficacy of pharmacotherapy, the use of long-acting injectable (LAI) antipsy-
chotics is considered an important treatment option. To date, many studies comparing LAIs and oral antipsychotics have been
conducted; however, the results are mixed, and careful interpretation of the data is required.
Study Design and Setting: Selective review of existing literature regarding LAIs. We especially focused the discussion on the impact
of the design of studies with different approaches comparing LAIs and oral antipsychotics in preventing relapse.
Result: The results were diverse and were influenced by the design used, that is, randomized controlled trials (RCTs) showed LAIs and
oral antipsychotics to have similar effects, whereas mirror-image and some large cohort studies showed LAIs to be superior to oral
antipsychotics.
Conclusion: Divergent results from studies using different methodologies create a dilemma for comparative effectiveness research,
and LAI studies may serve as an example of a situation in which a conventional RCT is not the gold standard. Traditional RCTs
generally increase adherence compared with clinical practice and, therefore, might not be well suited to detect differences between
LAIs and oral medications, because any increase in adherence affects patients on oral medications more than those on LAIs and thus
leads to an underestimation of any potential difference in effectiveness. A possible solution would be the implementation of a true
effectiveness trial in which post-randomization involvement would be kept to a minimum to better reflect routine practice.  2013
Elsevier Inc. All rights reserved.
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Key findings
 The results of the LAI studies differ considerably
depending on the design, for example, randomized
controlled trials (RCTs), mirror-image studies, and
naturalistic cohort studies.
What this adds to what was known?
 It is important to summarize the findings of differ-
ent types of studies to provide a framework for dis-
cussions about the appropriate methodology.
What is the implication and what should change
now?
 The traditional RCT is not necessarily the gold
standard for examining the effectiveness of LAIs.
 Future RCTs may benefit from including patients
at high risk for relapse and those most closely re-
flecting routine clinical care. In addition, a true
large simple trial might be most informative.of antipsychotic medications in the reduction of acute signs
and symptoms as well as the prevention of recurrence of
acute exacerbations. These effects are as dramatic as those
of many other widely accepted treatments in general med-
icine [1]. Patient adherence/compliance in taking pre-
scribed medications is one of the most challenging
aspects of health care [2]. This pertains both to full nonad-
herence and to partial nonadherence, which may be even
more common. Numerous studies of schizophrenia have
shown nonadherence to be a frequent problem and a com-
mon cause of relapse, rehospitalization, and the loss of
hard-won gains in psychosocial and vocational adjustment
[3]. At the same time, it has been demonstrated that both
patients and physicians underestimate the extent of nonad-
herence when their estimates are compared with more
objective measures [4]. The ability of health care pro-
viders and caregivers to identify and measure the degree
of nonadherence is also limited. The methods that are the
simplestdsuch as asking the patient directly or providing
a self-administered questionnaire to the patientdare the
least reliable. By contrast, the most accurate methodsd
observed ingestion or measured blood levelsdare intrusive,
costly, and not easily scalable [2].
A large proportion of nonadherence, even in severe psy-
chiatric illness, is not willful refusal to take medication. Pa-
tients might forget to take medication, which can be
exacerbated by illness sequelae, such as disorganization,
lack of insight, and/or cognitive dysfunction. In addition,
stigma, adverse effects, cost, and lack of perceived efficacy
can also play important roles [5].The distinction between efficacydthe impact of an in-
tervention under ideal conditionsdand effectivenessdthe
impact of an intervention in routine clinical practicedis
critical in designing and interpreting clinical trials. Because
nonadherence is one of the major drivers of differences in
a drug’s efficacy vs. effectiveness, the nature of the studies
done to assess the impact of medication strategies to en-
hance adherence becomes a particular challenge.2. Long-acting injectable antipsychotics
Long-acting injectable medications and implantable for-
mulations were intended to facilitate the benefits of medica-
tion by reducing the all-too-likely variability in ingestion.
There are now five long-acting injectable (LAI) formulations
of antipsychotic medications approved for use in the United
States. These medications can be given at intervals of 2e4
weeks depending on their specific pharmacokinetic properties.
It is likely that formulations with even longer injection inter-
vals will become available in the not-too-distant future.
In addition to providing ‘‘guaranteed’’ medication deliv-
ery, LAIs offer other potential advantages. Although when
administered LAIs do provide guaranteed medication, they
do not provide any overall guarantee that medication will
be received, in that a patient may choose to miss a sched-
uled injection. However, they do provide the advantage of
immediate awareness of nonadherence when it does occur,
that is, if a patient misses a scheduled injection, the treat-
ment team, family, or other caregiver becomes aware im-
mediately. When individuals are taking oral medication,
nonadherence is difficult to detect; the first indication might
be a worsening of the patient’s condition, which can be too
late to prevent further deterioration. In addition, given the
pharmacokinetic properties of LAIs, blood levels do not de-
cline as quickly after a missed injection as they would after
missing a dose of oral medication. This gives all interested
parties time to intervene before an exacerbation is likely.
Because LAIs are given parenterally, they also avoid some
interindividual differences in absorption and metabolism,
which in the case of antipsychotic drugs can lead to enor-
mous and generally unpredictable differences in blood
levels [6]. There is also less fluctuation from hour to hour
and day to day in the patient’s blood level. The use of LAIs
can go a long way toward reducing family tension and con-
flict about medication adherence. Such tensions can be the
result of insufficient symptom response secondary to (par-
tial) nonadherence; however, even in adherent patients, ten-
sion may be caused by family members’ perceived need to
check on or remind the patient to take medications.3. Assessing the comparative effectiveness of long-
acting injectable and oral antipsychotics
Despite the availability of a number of LAIs, their utili-
zation rates in the United States are substantially lower than
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number of potential reasons for this is beyond the scope
of this report. However, in the context of the present discus-
sion, it is important to emphasize that the evidence base
supporting the use of such agents is both inconsistent and
confusing.
Shortly after the introduction of LAIs, a number of
mirror-image studies demonstrated their potential in reduc-
ing rates of relapse and rehospitalization [8]. Mirror-image
studies involve comparing a period before an index event
(in this case starting an LAI) with an equal period after
the index event. In this analysis, each subject serves as
his/her own control. However, although mirror-image stud-
ies might suggest effectiveness, they also suffer from the
potential impact of other factors besides the introduction
of a new treatment, including expectancy bias and changes
in service provision and utilization.
The RCT has been the gold standard of comparative ef-
fectiveness, and a series of studies have been conducted
comparing LAIs with oral medications (either the same
specific molecule or an array of other comparable medica-
tions given in oral form). In such studies, an immediate
challenge is maintaining a double-blind design. One solu-
tion is the so-called ‘‘double-dummy’’ design in which all
patients regardless of assignment receive both injections
and oral medications, one of which is a placebo. Other
strategies have included using ‘‘masked’’ assessors while
the type of medication condition is known to the patient.
However, concerns have been raised about multiple masked
assessors at the same treatment center remaining consis-
tently blind to the treatment type. For this reason and con-
cerns regarding inter-rater reliability, some recent studies
have taken advantage of advances in videoconferencing
technology and used a small cadre of carefully trained
and supervised remote centralized raters who can more eas-
ily be kept blind to the treatment condition while maintain-
ing high levels of inter-rater reliability [9,10].
Other considerations in the conduct of RCTs in this con-
text are important, in that they might affect the clinical sig-
nificance and generalizability of the findings.
First of all, patient selection is a challenge. Should pa-
tients be identified for having demonstrated nonadherence
leading to a relapse? After all, nonadherence is often co-
vert, undetected, or undocumented when a relapse does oc-
cur. How likely are such patients to agree to participate in
a controlled clinical trial involving random assignment and
a variety of research assessments? Are patients who have
a history of or tendency toward nonadherence less likely
to participate in RCTs?
One approach to the identification of nonadherent pa-
tients is to focus on those who have been hospitalized with
a relapse within a specified time from before enrollment in
the RCT. The assumption is that because some substantial
proportion of these relapses is related to nonadherence,
an appropriate sample is being identified. The problem re-
mains that the proportion of such patients included ina particular RCT is unclear, and some populations of re-
cently hospitalized patients might overrepresent those at
risk for hospitalization for reasons other than problems in
medication adherence, for example, substance use/abuse,
lack of social support or housing, environmental stressors,
and so forth. The recent study by Rosenheck et al. [9] might
be an example of such a population and will be discussed
below.
The next concern is the design of the trial in terms of du-
ration, frequency of assessments, monitoring strategies, and
other factors that are part of the overall research effort.
There has been some suggestion that it is more difficult
to demonstrate differences between oral medication and
LAIs in short-term as opposed to long-term studies. The ra-
tionale is that patients might initially be adherent, that non-
adherence might take time to develop, and that the
consequences of nonadherence may take several or many
months to become apparent. We have previously reported
a simulation analysis supporting the possibility that studies
lasting 2 years would have substantially more likelihood of
detecting a difference than those lasting only 1 year [11].
Another issue in the design of such trials involves the
potential effect of the trial itself on patient outcomes (the
so-called Hawthorne effectdsuggesting that changes in
participants’ behavior during the course of a study may
be related only to the special social situation and social
treatment they received [12]). Given the potential for the in-
creased personal attention that is often associated with par-
ticipation in clinical trials, what role might that play in
reducing the risk of nonadherence and/or relapse in a popu-
lation of patients with schizophrenia? Patients are often
sent reminders to attend their appointments for research as-
sessments. In some studies, the medication (either oral or
LAI) is provided free to patients and, in the case of the oral
drug, even handed to them as one of the incentives for par-
ticipating in a trial or to have the ‘‘same’’ conditions for the
LAI and oral medication groups, thereby seriously altering
the ecological validity of the study. This provision of oral
medications eliminates the need to take a prescription to
the pharmacy, which is one point at which patient require-
ments for initiative might be quite different under normal
circumstances. Frequent assessments can be more likely
to detect early signs of relapse, allowing the opportunity
for clinical intervention to prevent a full-blown relapse in
patients receiving oral antipsychotics. This might further
diminish the potential advantages of an LAI in clinical tri-
als compared with real-world settings.4. Results of RCTs
In a meta-analysis published in 2011 [13], we reviewed
10 studies lasting at least 12 months comparing outpatients
randomly assigned to LAI or oral medication. Although
there were differences in patient characteristics as well as
assessment and outcome measures across studies, the
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over oral antipsychotics. With 1,700 subjects included in
the trials, data on relapse (primary outcome), rehospitaliza-
tion, nonadherence, dropout because of any cause, ineffi-
cacy of treatment, and adverse effects were summarized
in a meta-analysis using a random-effects model. Depot
formulations significantly reduced relapses, with relative
risk (RR) and absolute risk reductions of 30% and 10%,
respectively (RR 5 0.70, confidence interval [CI] 5
0.57e0.87, number needed to treat [NNT] 5 10,
CI 5 6e25, P 5 0.0009). Furthermore, LAIs also reduced
dropout because of inefficacy by 29% (RR 5 0.71,
CI 5 0.57e0.89). Depot antipsychotic drugs also signifi-
cantly reduced rehospitalization, but because of a number
of methodological differences and problems in the individ-
ual trials, the evidence was not conclusive.
However, in contrast to these meta-analytic findings, two
more recent, large-scale, government-funded studies did
not demonstrate the superiority of LAIs over oral medica-
tion. One study [9] randomly assigned 369 patients in the
Veteran Affairs (VA) system who had been hospitalized
within the previous 2 years or who were at imminent risk
for hospitalization to either 25 or 50 mg long-acting inject-
able risperidone or to a psychiatrist’s choice of oral antipsy-
chotics. Forty percent of patients were hospitalized at the
time of randomization. The rate of (re)hospitalization (the
primary outcome measure) was 39% on LAI medication
after 10.8 months vs. 45% on oral medication after
11.3 months: hazard ratio, 0.87; 95% CI 0.63e1.20. Al-
though the difference between LAI and oral medication
was nonsignificant, the most striking feature of these results
is the extremely high rehospitalization rates for both
groups. A 39% rehospitalization rate after 10.8 months on
depot medication is extremely high, particularly given the
contemporary hospitalization usage (studies done 20 or
more years ago might reflect a higher likelihood of use of
hospital beds). This raises the important consideration that
in this particular patient population from the VA system,
37% of whom had active alcohol or substance use, there
was high risk of readmission to hospital for reasons other
than relapse because of nonadherence. The potential value
of LAI treatment depends on reducing the rates of nonad-
herence; otherwise, there is no evidence that one formula-
tion is more effective in preventing relapse than another.
A second study funded by the National Institute of Men-
tal Health [14] randomized 305 outpatients who had expe-
rienced a relapse within the prior year, but not within the
past month, to LAI risperidone or an oral second-
generation antipsychotic. Patients were followed up for
2 years. Those on LAI had a relapse rate not significantly
different from those on oral medication. This population
did not have the same characteristics as the study by Rosen-
heck in terms of chronicity, high prevalence of substance
abuse, or high rates of rehospitalization in both treatment
groups. However, differences in relapse rates might have
been minimized by the nature of the research effort, with,for example, patients being given their oral medication
supplies as part of their regularly scheduled visit, and so
forth.
Kishimoto [15] presented data from a more recent meta-
analysis that included 21 RCTs including the two that were
just discussed. This meta-analysis failed to show superiority
of LAIs over oral medications (n 5 4,950, RR 5 0.93, 95%
CI 5 0.80e1.08, P 5 0.35). This meta-analysis is poten-
tially vulnerable to a cohort bias in that significant advan-
tages of LAI medications were more likely to be seen in
studies published before 1992 (and involving only first-
generation LAIs) than in those published after 2004 (and in-
volving only second-generation LAIs) and a data set limited
by no direct comparisons between first- and second-
generation LAIs.
Tiihonen et al. [16,17] reported on two large-scale, ob-
servational, follow-up studies using a national registry of
patients with schizophrenia in Finland. In both these re-
ports, one of which involved patients who had experienced
only one prior hospitalization, LAIs were associated with
significantly lower rates of hospitalization than were oral
medications. If anything, this methodology might be con-
sidered to have a conservative bias, in that physicians mak-
ing a decision to use LAIs for a particular patient are most
likely basing that decision on some clinical information,
such as prior difficulty with or reluctance to take oral med-
ication, history of poor adherence, and so forth. Given the
possibility of selection bias, the finding regarding the supe-
riority of LAIs could be viewed as even more striking. In
addition, a naturalistic sample includes all patients receiv-
ing treatment in a particular data set and during a particular
period and is not restricted to patients who have proven to
be eligible for and consented to an often complex and de-
manding RCT. Therefore, patients involved in a naturalistic
data analysis are likely to be more representative of ‘‘real-
world’’ patients and settings, yielding findings that are
likely to be more generalizable.5. Lessons to be learned for effectiveness research
These diverging results from studies using very different
methodologies create an interesting dilemma for compara-
tive effectiveness research and perhaps serve as an example
of a situation in which the traditional RCT is less likely to
provide valid information than other study designs.
All clinical RCTs have limitations in generalizability;
however, when the study has a particular focus on nonad-
herence and its consequences, it may well be that the
RCT by its very nature has too much impact on the primary
outcome measure, thereby diminishing the possibility of
detecting potentially meaningful differences between alter-
native treatment approaches.
A possible solution to this challenge would be the im-
plementation of a true ‘‘effectiveness trial’’ (a prospective
RCT that uses broad inclusion criteria, multiple study
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clinical practice under real-world conditions of use).
Such a study should be conducted comparing LAIs and
oral antipsychotics. Ideally, it should focus on patients in
a relatively early phase of illness, before a potential pattern
of multiple relapses and severe decrement in psychosocial
functioning has already been established. Patients should
be followed up for at least 2 years, with the primary out-
come measures being relapse and/or hospitalization, which
can be verified by relatively objective measures. No other
requirements for frequency of visits or standardized assess-
ment should be used. Patients would still have to consent to
the randomization, which would potentially exclude a sig-
nificant proportion of subjects, particularly because one
arm of the study involves injections; there would be no get-
ting around this as a methodological problem. Data from
such a trial would provide useful additional information
on a comparative effectiveness question that remains an
enormous public health issue and has proven to be a consid-
erable challenge to study.References
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